Every Form 4 that Mirum Pharmaceuticals (MIRM) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow MIRM and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full MIRM filings page.
Mirum Pharmaceuticals, Inc. (MIRM) reported that Jolanda Howe, its Senior Vice President and Global Controller, sold 658 shares of common stock on September 2, 2026 in a sale described as occurring in the open market or a private transaction at $100.00 per share.
After this sale, Howe held 616 shares of Mirum common stock directly. The transaction was carried out pursuant to a Rule 10b5-1 trading plan adopted by Howe on March 18, 2026, indicating it was pre-arranged.
Mirum Pharmaceuticals, Inc. (MIRM) reported that Chief Executive Officer Christopher Peetz exercised fully vested stock options for 30,000 shares of common stock on September 1, 2026 at an exercise price of $2.936 per share, receiving 30,000 shares of common stock. On the same date, he sold 8,312 shares at a weighted average price of $98.08 per share and 21,688 shares at a weighted average price of $98.91 per share under a Rule 10b5-1 trading plan adopted on March 2, 2026. Following the option exercise, he held 58,487 stock options directly and 187,500 shares of common stock indirectly through The Peetz Family Trust.
Mirum Pharmaceuticals, Inc. (MIRM) reported insider equity transactions by Jolanda Howe, its SVP, Global Controller. On 2026-08-18, Howe exercised 40,000 employee stock options at an exercise price of $6.27 per share, acquiring an equal number of common shares. On the same date, she sold 40,000 common shares at $100.00 per share in a transaction described as a sale in an open market or private transaction. The option grant was fully vested at the time of exercise, and the option position reported in this filing was reduced to zero.
Mirum Pharmaceuticals, Inc.'s Chief Financial Officer, Eric Bjerkholt, reported a sale of 6,001 shares of common stock on August 11, 2026 at a weighted average price of $99.90 per share, in a transaction described as a sale in the open market or a private transaction. The sale was executed pursuant to a Rule 10b5-1 trading plan adopted on March 9, 2026. Following this transaction, Bjerkholt beneficially owns 36,355 shares of Mirum common stock, including 175 shares acquired on May 10, 2026 under the Employee Stock Purchase Plan.
Mirum Pharmaceuticals, Inc. CEO Christopher Peetz exercised an employee stock option for 20,000 shares of common stock at an exercise price of $2.936 per share and received 20,000 shares on August 10, 2026. On the same date he sold a total of 20,000 common shares in three tranches at weighted average prices of $98.51, $99.25, and $100.14 per share pursuant to a Rule 10b5-1 Plan. Following the option exercise, he reported 88,487 stock options remaining and an indirect holding of 187,500 shares held by The Peetz Family Trust.
Mirum Pharmaceuticals, Inc. senior vice president and global controller Jolanda Howe sold 1,840 shares of Common Stock on August 3, 2026 at a price of 105.2900 in an open-market or private transaction executed under a Rule 10b5-1 trading plan adopted on March 18, 2026.
After this sale, Howe directly held 1,274.0000 shares of Mirum Common Stock.
Mirum Pharmaceuticals CEO Christopher Peetz exercised stock options for 20,000 shares of common stock at $2.936 per share and sold 20,000 shares in open-market transactions on July 6, 2026 under a Rule 10b5-1 Plan. Following these trades, he holds 196,019 shares directly and 187,500 shares indirectly through The Peetz Family Trust.
Mirum Pharmaceuticals’ chief financial officer Eric Bjerkholt sold 5,000 shares of common stock in open-market transactions. The sales occurred on July 6, 2026 at prices reported between about $121.13 and $124.94 per share, pursuant to a pre-arranged Rule 10b5-1 plan. Following these transactions, he continues to own 42,181 shares directly.
Mirum Pharmaceuticals SVP and global controller Jolanda Howe reported an open-market sale of 2,721 shares of common stock at $120.00 per share. After the transaction, she directly holds 3,114 shares. The filing notes the sale was executed under a pre-arranged Rule 10b5-1 trading plan adopted on March 18, 2026, indicating it was scheduled in advance rather than timed discretionarily.
Mirum Pharmaceuticals SVP Jolanda Howe reported an open-market sale of 2,594 shares of Common Stock at $101.95 per share. After this transaction, she directly holds 5,835 shares. The filing notes the sale was made under a pre-arranged Rule 10b5-1 trading plan adopted on March 18, 2026, indicating the timing was scheduled in advance.
Mirum Pharmaceuticals, Inc. director Timothy P. Walbert reported equity awards consisting of restricted stock units and stock options. He received 1,980 restricted stock units, each representing a right to receive one share of common stock, and 3,772 stock options with an exercise price of $101.00 per share.
Both the RSUs and options vest on the first anniversary of the June 15, 2026 grant date, but will in any case be fully vested on the date of Mirum’s 2027 annual stockholder meeting. After these awards, Walbert holds 1,980 RSUs and 3,772 options directly, reflecting compensation-related grants rather than open‑market trades.
Mirum Pharmaceuticals director Lon Cardon received new equity awards as part of his compensation. He was granted 1,980 restricted stock units, each representing the right to receive one share of common stock, and 3,772 stock options with an exercise price of $101.00 per share.
Both the RSUs and options vest on the first anniversary of the June 15, 2026 grant date, and in any event will be fully vested by the company’s 2027 annual stockholder meeting. After these awards, Cardon directly holds 1,980 RSUs and 3,772 options, with no shares bought or sold in this filing.
Mirum Pharmaceuticals director Saira Ramasastry reported new equity awards. She received 1,980 restricted stock units and stock options for 3,772 shares of common stock with an exercise price of 101 per share. Both awards vest on the first anniversary of the grant date, or earlier if fully vested by Mirum’s 2027 annual stockholder meeting. The options expire on June 14, 2036. These are compensation-related grants rather than open-market purchases or sales.
Mirum Pharmaceuticals director William Fairey reported new equity awards consisting of deferred stock units and stock options. He received 1,980 deferred stock units and options for 3,772 shares of common stock at an exercise price of $101.00 per share, all as compensation awards.
The options and deferred stock units vest on the first anniversary of the grant date, and in any case will be fully vested by the date of Mirum’s 2027 annual stockholder meeting. Each vested deferred stock unit will be settled in common stock upon a change in control of Mirum or within 60 days after his separation from service.
Mirum Pharmaceuticals director Laura Brege reported equity awards consisting of deferred stock units and stock options. She received 1,980 deferred stock units, each representing a contingent right to one share of common stock, and 3,772 stock options to buy common stock at an exercise price of $101.00 per share.
Both the options and deferred stock units vest on the first anniversary of the June 15, 2026 grant date, and in any case will be fully vested by the company’s 2027 annual stockholder meeting. The options expire on June 14, 2036. Vested deferred stock units will be settled in common stock upon a change in control of Mirum or within 60 days after Brege’s separation from service.
Mirum Pharmaceuticals director Patrick J. Heron received new equity awards as part of his compensation. He was granted 1,980 deferred stock units and 3,772 stock options, each option giving the right to buy one share of common stock at an exercise price of $101.00 per share.
The stock options and deferred stock units vest on the first anniversary of the grant date, and in any case will be fully vested by the date of Mirum’s 2027 annual stockholder meeting. Each vested deferred stock unit will be settled in common stock upon a change in control of Mirum or within 60 days after his separation from service. These are grants and not open‑market purchases or sales.
Mirum Pharmaceuticals director Laurent Fischer received new equity awards in the form of deferred stock units and stock options. The filing shows a grant of 1,980 deferred stock units and 3,772 stock options, each tied to Mirum common stock.
The stock options carry an exercise price of $101.00 per share and expire on June 14, 2036. Both the options and deferred stock units vest on the first anniversary of the June 15, 2026 grant date, and in any case are fully vested by the date of Mirum’s 2027 annual stockholder meeting.
Each deferred stock unit represents a right to receive one share of common stock. Vested deferred stock units will be settled in stock upon the earlier of a change in control of Mirum or within 60 days after Fischer’s separation from service with the company.
GREY MICHAEL G reported acquisition or exercise transactions in this Form 4 filing.
Mirum Pharmaceuticals director Michael G. Grey received new equity compensation awards. On June 15, 2026, he was granted 1,980 restricted stock units, each representing a right to receive one share of common stock, and 3,772 stock options exercisable at $101.00 per share.
Both the RSUs and options are scheduled to vest on the first anniversary of the grant date, but will in any case be fully vested on the date of Mirum’s 2027 annual stockholder meeting. After these grants, Grey directly holds 1,980 RSUs and 3,772 options, with the options expiring on June 14, 2036.
Mirum Pharmaceuticals, Inc. Chief Financial Officer Eric Bjerkholt exercised stock options and sold shares in the company. On June 9, 2026, he exercised 2,393 Employee Stock Options at an exercise price of $26.49 per share, receiving the same number of common shares. On June 8, 2026, he sold a total of 5,000 common shares in open-market transactions at weighted average prices of $92.84, $93.95 and $95.12, within the disclosed trading ranges. The filing states these transactions were made pursuant to a pre-arranged Rule 10b5-1 Plan. Following these transactions, Bjerkholt directly owns 47,181 common shares of Mirum Pharmaceuticals.
Mirum Pharmaceuticals President and COO Peter Radovich exercised stock options to acquire 16,988 shares of common stock at $19.19 per share. These options were fully vested at the time of exercise. After the transaction, he directly holds 57,260 shares of Mirum common stock.
Following the exercise, Radovich still holds 48,012 stock options with an exercise price of $19.19 per share, expiring on January 6, 2031. The filing reflects a derivative exercise only, with no open-market share sales reported in this transaction.
Mirum Pharmaceuticals, Inc. director and chief executive officer Christopher Peetz reported option exercises and share sales in the company’s stock. On June 1, 2026, he exercised stock options for 30,000 shares of common stock at an exercise price of $2.936 per share and sold 30,000 shares of common stock in multiple open-market transactions. The sales occurred at prices ranging from about $93.90 to $99.79 per share pursuant to a pre-arranged Rule 10b5-1 Plan adopted on March 2, 2026. Following these transactions, he holds 194,309 shares of common stock directly and 187,500 shares indirectly through The Peetz Family Trust, as well as 128,487 stock options outstanding.
Director Timothy P. Walbert of Mirum Pharmaceuticals, Inc. exercised previously granted restricted stock units that converted into 3,977 shares of common stock on May 29, 2026. These units represented a contingent right to receive one share of common stock for each unit.
After the transaction, Walbert directly holds 9,680 shares of common stock. The filing shows a routine compensation-related derivative exercise, with no open-market buying or selling and no remaining restricted stock units from this grant.
Mirum Pharmaceuticals director Lon Cardon exercised 3,977 restricted stock units into common stock. These units each converted into one share on May 29, 2026, increasing his directly held common stock to 9,680 shares. The filing shows an equity award vesting, with no open‑market buying or selling.
Mirum Pharmaceuticals director Saira Ramasastry reported an exercise-and-sale transaction involving 3,977 shares of common stock. On May 29, 2026, 3,977 restricted stock units were converted into 3,977 shares of common stock at a stated price of $0.0000 per share. On June 1, 2026, all 3,977 shares were sold in an open-market transaction at $100.0000 per share, leaving 0 shares of common stock reported as directly held after the sale. The filing notes that the sale was carried out under a pre-arranged Rule 10b5-1 trading plan adopted on September 18, 2025, indicating the timing was set in advance.
Mirum Pharmaceuticals director Laurent Fischer exercised restricted stock units into common shares. On May 29, 2026, 3,977 restricted stock units, each representing a right to receive one share of common stock, were converted into 3,977 shares of Mirum common stock. Following this derivative exercise, Fischer directly holds 10,727 shares of common stock. The restricted stock units represented a contingent right that vested on May 29, 2026.
Mirum Pharmaceuticals, Inc. director Saira Ramasastry reported an exercise-and-sell transaction in company stock. On May 15, 2026, she exercised stock options to acquire 2,000 shares of common stock at $23.51 per share, then sold 2,000 shares in an open-market transaction at $109.47 per share. The filing shows these trades were executed under a pre-arranged Rule 10b5-1 trading plan adopted on September 18, 2025, indicating they were scheduled in advance. After these transactions, her reported direct common stock holdings were 0 shares, and the exercised option covering 2,000 shares is fully vested and fully exercised.
Mirum Pharmaceuticals director Saira Ramasastry exercised options and sold the resulting shares in a planned transaction. On April 15, 2026, she exercised a stock option to acquire 2,000 shares of Mirum common stock at $23.51 per share, from a fully vested option. The same day, she sold 2,000 common shares in an open-market transaction at $96.90 per share, leaving 0 shares of common stock reported as directly owned after the sale. The filing notes the activity occurred under a Rule 10b5-1 trading plan adopted on September 18, 2025, indicating the trades were pre-arranged.
Mirum Pharmaceuticals’ Chief Financial Officer Eric Bjerkholt exercised performance-based equity and sold shares mainly to cover taxes. He converted 13,334 performance restricted stock units into common stock at a conversion price of $0.0000 per unit. On the next trading day, 7,287 common shares were sold at an average price of $91.9779 per share to satisfy tax withholding obligations tied to this vesting. After these transactions, he directly held 49,788 shares of Mirum common stock.
Mirum Pharmaceuticals chief medical officer Joanne Quan exercised performance-based stock awards and sold shares mainly to cover taxes. On March 15, 2026, she exercised 13,334 performance restricted stock units, receiving the same number of Mirum common shares at a $0 exercise price, leaving 6,666 units outstanding. On March 16, 2026, she sold 7,287 shares of common stock in an open-market transaction at an average price of $91.9779 per share to satisfy tax withholding obligations tied to the vesting. After these transactions, Quan directly owned 18,864 Mirum common shares. The remaining performance units are scheduled to vest with two-thirds on March 15, 2026 and one-third on March 15, 2027, as described in the filing.
Mirum Pharmaceuticals director Saira Ramasastry exercised stock options and sold the resulting shares. On March 16, 2026, she exercised options for 2,000 shares of common stock at an exercise price of $23.51 per share, then sold 2,000 shares in an open‑market transaction at $90.76 per share.
The filing shows she no longer directly holds these 2,000 common shares after the sale. The transactions were carried out under a pre‑arranged Rule 10b5‑1 trading plan adopted on September 18, 2025, indicating they were scheduled in advance rather than timed discretionarily.
Mirum Pharmaceuticals president and COO Peter Radovich reported a combination of equity award vesting and share sales. He exercised performance restricted stock units into 30,220 shares of common stock at a conversion price of $0.00 per share, increasing his direct holdings.
On the following day, he sold 16,515 common shares at an average price of $91.9779 per share, with a footnote stating the sale was to cover tax withholding obligations from the RSU vesting. After these transactions, he directly holds 40,272 common shares and continues to hold 11,500 performance restricted stock units scheduled to vest over future dates.
Mirum Pharmaceuticals, Inc. senior vice president and global controller Jolanda Howe exercised performance restricted stock units into 8,658 shares of common stock, each unit representing one share. On March 16, 2026, she sold 4,732 common shares at 91.9779 per share to cover tax withholding obligations related to this vesting, and held 8,429 shares afterward. Footnotes state the performance restricted stock units vest in stages over March 15, 2025–2027.
Mirum Pharmaceuticals CEO Christopher Peetz reported a mix of stock exercises and a tax-related sale. On March 15, 2026, he exercised performance restricted stock units covering 75,000 shares of common stock at a conversion price of $0.00, increasing his direct holdings.
On March 16, 2026, Peetz executed an open-market sale of 40,985 shares of common stock at an average price of $91.9779 per share. A footnote states these shares were sold to cover tax withholding obligations tied to the vesting of the performance restricted stock units, indicating a mechanistic, tax-driven transaction rather than a discretionary sale. After these transactions, he directly held 194,309 shares, with an additional 187,500 shares held indirectly by The Peetz Family Trust.
Mirum Pharmaceuticals president and COO Peter Radovich exercised stock options to acquire 5,912 shares of common stock at an exercise price of $15.87 per share. These options were fully vested. Following the transaction, he directly owns 26,567 shares of common stock and holds 54,088 stock options.
No shares were sold and no tax-withholding dispositions were reported, making this a straightforward exercise-and-hold transaction that increases his direct equity stake in the company.
Mirum Pharmaceuticals director Saira Ramasastry reported an option exercise and share sale. On February 13, 2026, she exercised stock options covering 2,000 shares of common stock at an exercise price of $23.51 per share, converting a derivative position into shares.
On the same day, she then sold 2,000 shares of common stock in an open-market transaction at a price of $102.09 per share, leaving 0 common shares owned directly after the sale and 6,000 stock options held directly. The filing states the sale occurred under a Rule 10b5-1 trading plan adopted on September 18, 2025, and notes that the stock option involved is fully vested.
Mirum Pharmaceuticals President and COO Peter Radovich reported a sale of company common stock in a Form 4 filing. On February 2, 2026, he sold 2,631 shares of common stock at an average price of $103.3035 per share. According to the footnote, the shares were sold to cover tax withholding obligations associated with the vesting of restricted stock units. After this transaction, he beneficially owned 20,655 shares of Mirum Pharmaceuticals common stock directly.
Mirum Pharmaceuticals, Inc.’s chief executive officer and director Christopher Peetz reported a sale of 9,108 shares of common stock on February 2, 2026 at a price of $103.3035 per share. The filing states these shares were sold to cover tax withholding obligations from vesting restricted stock units.
After this transaction, Peetz beneficially owned 160,294 Mirum common shares directly and 187,500 shares indirectly through The Peetz Family Trust. This reflects a routine, tax-related insider transaction rather than an open-market discretionary sale.
Mirum Pharmaceuticals SVP and Global Controller Jolanda Howe reported routine equity compensation activity. On January 31, 2026, 1,771 restricted stock units vested and were converted into an equal number of common shares at an exercise price of $0.
On February 2, 2026, Howe sold 968 shares of common stock at a price of $103.3035 per share to cover tax withholding obligations related to the vesting. After these transactions, Howe directly owned 4,503 shares of Mirum Pharmaceuticals common stock.
Mirum Pharmaceuticals senior vice president and global controller Jolanda Howe reported new equity awards in the company. On January 28, 2026, she received stock options for 7,680 shares of common stock with an exercise price of $100.85 per share, vesting over four years starting one year after that date.
She was also granted 4,970 restricted stock units, each representing one share of common stock. These RSUs vest in three equal annual installments on each anniversary of January 28, 2026. In addition, 9,000 performance restricted stock units previously granted on January 23, 2024 were confirmed to have met their performance criteria, and will vest two-thirds on March 15, 2026 and one-third on March 15, 2027.
Mirum Pharmaceuticals reported new equity awards for its Chief Medical Officer, Joanne Quan, dated January 28, 2026. She received a stock option for 18,140 shares at an exercise price of $100.85 per share. One quarter of this option vests one year after January 28, 2026, with the remaining shares vesting in 36 equal monthly installments.
Quan was also granted 11,760 restricted stock units (RSUs), each representing one share of common stock. These RSUs vest in three equal annual installments on each anniversary of January 28, 2026. In addition, 20,000 performance restricted stock units (PSUs) granted on January 23, 2024, had their performance criteria determined to be met on January 28, 2026. Two thirds of the PSU shares will vest on March 15, 2026 and the remaining one third on March 15, 2027.
Mirum Pharmaceuticals' chief financial officer Eric Bjerkholt received new equity awards on January 28, 2026. He was granted stock options for 18,140 shares of common stock at an exercise price of $100.85 per share, plus 11,760 restricted stock units and 20,000 performance-based restricted stock units.
The stock options vest over four years, with one-quarter vesting one year after January 28, 2026 and the remainder in 36 equal monthly installments. The restricted stock units vest in three equal annual installments from the same date. The performance units vest two-thirds on March 15, 2026 and one-third on March 15, 2027 after performance criteria were met.
Mirum Pharmaceuticals’ President and COO Peter Radovich reported new equity awards dated January 28, 2026. He received a stock option for 25,120 shares of common stock at an exercise price of $100.85 per share.
He was also granted 16,280 restricted stock units, each representing one share of common stock, vesting in three equal annual installments starting January 28, 2027. In addition, 34,500 performance restricted stock units tied to performance criteria that were determined met on January 28, 2026 will vest as follows: two-thirds on March 15, 2026 and the remaining one-third on March 15, 2027. All awards are reported as directly owned.
Mirum Pharmaceuticals, Inc. CEO and director Christopher Peetz reported new equity awards, including stock options and stock units granted on January 28, 2026. He received stock options for 67,000 shares at an exercise price of $100.85, vesting over four years starting one year after the vesting commencement date.
Peetz was also granted 43,500 restricted stock units, vesting in three equal annual installments on each anniversary of January 28, 2026. In addition, 75,000 previously granted performance restricted stock units had their performance criteria confirmed as met; two-thirds of these shares vest on March 15, 2026 and one-third on March 15, 2027. All reported derivative holdings are listed as directly owned.
Mirum Pharmaceuticals’ chief financial officer Eric Bjerkholt reported routine equity compensation activity. On January 23, 2026, 2,667 restricted stock units vested and converted into the same number of common shares at an exercise price of $0. On January 26, 2026, he sold 1,053 of these shares at $96.192 per share to cover tax withholding obligations linked to the vesting. After these transactions, he directly owns 43,741 shares of common stock and 2,666 restricted stock units, which continue to vest in equal annual installments through the three-year schedule that began January 23, 2024.
Mirum Pharmaceuticals’ president and COO Peter Radovich reported routine equity transactions. On January 23, 2026, 5,750 restricted stock units vested and were converted to 5,750 shares of common stock at an exercise price of $0, increasing his directly held common shares to 26,429.
On January 26, 2026, he sold 3,143 shares of common stock at $96.192 per share, mainly to cover tax withholding on the vesting. After these transactions, he directly owned 23,286 shares of Mirum common stock and 5,750 restricted stock units, which continue to vest in thirds on each anniversary of January 23, 2024.
Mirum Pharmaceuticals SVP and Global Controller Jolanda Howe reported routine equity transactions. On January 23, 2026, 1,500 restricted stock units vested and converted into 1,500 shares of common stock at an exercise price of $0, increasing her directly held common stock to 4,542 shares.
On January 26, 2026, Howe sold 842 shares of Mirum common stock at $96.192 per share to cover tax withholding obligations tied to the RSU vesting. After these transactions, she directly owned 3,700 shares of common stock and 1,500 restricted stock units, which continue to vest in thirds annually from January 23, 2024.
Mirum Pharmaceuticals chief executive Christopher Peetz reported routine equity activity involving company stock. On January 23, 2026, he exercised 12,500 restricted stock units, each converting into one share of common stock at an exercise price of $0, increasing his direct holdings to 176,233 shares.
On January 26, 2026, Peetz sold 6,831 shares of common stock at $96.192 per share, with the filing stating these shares were sold to cover tax withholding tied to the RSU vesting. After the sale, he directly owned 169,402 shares and also beneficially owned 187,500 shares indirectly through The Peetz Family Trust.
Mirum Pharmaceuticals director Patrick J. Heron reported indirect fund activity in Mirum stock. On January 23, 2026, Frazier Life Sciences X, L.P., an investment fund associated with him, received 159,277 shares of Mirum common stock in connection with the merger of Bluejay Therapeutics into Mirum, when Mirum’s closing share price was $94.29. That same day, Frazier Life Sciences X, L.P. also purchased 131,425 shares of Mirum common stock at $68.48 per share.
After these transactions, Frazier Life Sciences X, L.P. held 459,010 Mirum shares indirectly reported by Heron, and Frazier Life Sciences IX, L.P. held 3,566,912 shares. Heron also reported 5,703 Mirum shares held directly in his own name. The footnotes state that the Frazier funds hold the shares directly and that Heron disclaims beneficial ownership of those fund-held securities except to the extent of his pecuniary interest.
Mirum Pharmaceuticals senior vice president and global controller Jolanda Howe reported equity transactions tied to the vesting of restricted stock units. On January 21, 2026, 1,542 restricted stock units were converted into the same number of common shares at an exercise price of $0, reflecting the scheduled vesting of her award. On January 22, 2026, 926 common shares were sold at an average price of $93.3252 to cover tax withholding obligations related to this vesting. After these transactions, Howe directly held 3,042 shares of common stock and 3,083 restricted stock units, which continue to vest in equal annual installments through the third anniversary of January 21, 2025.
Mirum Pharmaceuticals chief medical officer Joanne Quan reported routine equity compensation activity and a related stock sale. On January 21, 2026, 3,334 restricted stock units vested and were converted into the same number of Mirum common shares, increasing her directly held stake to 14,639 shares. The filing notes that each restricted stock unit represents a right to receive one share of common stock or its cash equivalent at the issuer’s discretion.
On January 22, 2026, Quan sold 1,822 shares of common stock at an average price of $93.3252 per share to cover tax withholding obligations tied to the vesting. After these transactions, she directly owned 12,817 shares of Mirum common stock and held 6,666 restricted stock units, which are scheduled to vest in equal thirds on each anniversary of January 21, 2025 until fully vested after three years.